Clin2
NCT06909383Worth exploringNot yet recruiting

A drug for appetite and weight loss in advanced lung cancer

Extensive-stage Small Cell Lung Cancer (ES-SCLC)Cancer - Associated Anorexia - Cachexia Syndrome

Treatments studied

Part of Cancer, Lungs & breathing clinical trials.

This trial tests a medicine called nanocrystalline megestrol acetate to help people with advanced small cell lung cancer who have lost weight and appetite. The goal is to see if the drug can improve their condition.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
41 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must have a type of lung cancer called extensive-stage small cell lung cancer.
  • You should not have had chemotherapy for cancer that has spread, though some prior treatments are allowed if your cancer came back more than 6 months later.
  • You must have lost weight or have poor appetite (pre-cachexia or cachexia).
  • You cannot have untreated brain tumors that are causing symptoms.
  • You cannot be taking other medicines that increase appetite or weight.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06961201Not yet recruiting· Phase 3
Appetite medicine study for lung cancer with weight loss

This trial tests a new appetite-boosting medicine (nano-crystalline megestrol acetate) added to standard chemotherapy for people with advanced small cell lung cancer who are losing weight. It aims to see if it helps with weight, strength, and treatment response.

Chengdu, Sichuan
NCT07092137Not yet recruiting· Phase 2
Nano megestrol for appetite and weight loss in advanced lung cancer

This trial tests a nano form of megestrol acetate, a drug that may help improve appetite and reduce weight loss in people with advanced lung cancer who have already lost weight or have signs of inflammation. It's for those who have not yet had chemotherapy for advanced disease.

NCT06793228Not yet recruiting· Phase 2
A trial for advanced small cell lung cancer with weight loss

This trial tests a combination of nanocrystalline megestrol (a medicine to improve appetite and weight) with standard chemotherapy and immunotherapy as a first treatment for people with extensive-stage small cell lung cancer who have lost weight or have early signs of cachexia (wasting syndrome). The goal is to see if this approach can help you feel better and live longer.

Luoyang, Henan
NCT06828757Not yet recruiting· Phase 3
Nanocrystalline megestrol for weight loss in lung cancer

This trial tests if a new form of megestrol (a medicine that can increase appetite) helps people with advanced lung cancer who are losing weight. It is for patients who have not yet received chemotherapy for their cancer and are at risk of malnutrition.

Changsha, Hunan
NCT07356037Not yet recruiting· Phase 3
Nanocrystalline megestrol acetate for liver cancer wasting

This trial tests a drug called nanocrystalline megestrol acetate to help people with advanced liver cancer who are losing weight and muscle mass. It's for those who have not yet had systemic therapy and are receiving other cancer treatments at the same time.

Chengdu, Sichuan
NCT07477808Not yet recruiting· Phase 3
Megestrol acetate for advanced lung cancer with weight loss

This trial tests whether a medicine called megestrol acetate can help improve appetite and weight in people with advanced lung cancer who are malnourished. It's for those who haven't had chemotherapy for their advanced cancer yet.

Hear when a new Extensive-stage Small Cell Lung Cancer (ES-SCLC) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.